Supporting evidence

• LedgerRevenue trend: accelerating
• LedgerStrong quarter based on: Positive preclinical data for GLIX1 · Potential for combination therapy in ovarian cancer · Reinforcement of synthetic lethality mechanism.
• GuidanceGuidance: BioLineRx is maintaining its cash runway guidance into the first half of 2027.

• LedgerRevenue +67% YoY (Q1 FY2026)
• EventPositive Preclinical Results
• EventPipeline Advancement
• EventPartnership Collaboration
• EventPositive, reinforces the potential of GLIX1 and the synthetic lethality approach in oncology.
• EventRepresents a significant step forward in the clinical development of GLIX1, moving from preclinical to human trials, and opens up potential for new revenue streams.
• EventIncreases visibility and scientific validation for GLIX1, potentially attracting further investment and partnerships. The data on TMZ-resistant models is particularly promising for…
• InitiativeInitiated Phase 1/2a study in glioblastoma; ongoing pre-clinical activities for additional indications.
• InitiativeEnrollment is continuing.
• InitiativeEnrollment accelerated in CheMo4METPANC Phase 2b trial; second SCD study sponsored by St. Jude continues to enroll patients; final results from a Phase 1 SCD trial presented.
• InitiativePreparing for Phase 1/2a trial in glioblastoma, conducting pre-clinical studies for other cancers, and secured key patent protection.
• EventEarly-stage data
• EventTranslational risk to human trials